Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic HCT for High Grade CNS Malignancies
NCT04521946Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2021
- Primary completion
- Dec 2022
- Modality
- Peptides, Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of leuprolide in central nervous system malignancy, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Transplant-related mortality at Day 30 and Rate of grade III or higher organ toxicity attributable to conditioning. Planned start Jan 2021; status: withdrawn.
02
Drugs
leuprolide
03
Conditions
central nervous system malignancy
Beyond the preview
Go deeper on NCT04521946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04521946.